USEFULNESS OF PREOPERATIVE LOW-DOSE CISPLATIN TREATMENT FOR ADVANCED ESOPHAGEAL CANCER

被引：12

作者：

IMAMURA, M

SHIMADA, Y

KANDA, Y

FUKUMOTO, M

YANAGIBASHI, K

MIYAHARA, T

TOBE, T

机构：

[1] First Department of Surgery, Faculty of Medicine, Kyoto University, Kyoto, 606, 54 Shogoin-Kawaracho, Sakyo-ku

[2] First Department of Pathology, Faculty of Medicine, Kyoto University, Kyoto, 606, 54 Shogoin-Kawaracho, Sakyo-ku

来源：

SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY | 1992年 / 22卷 / 05期

关键词：

ESOPHAGEAL CANCER; PREOPERATIVE CISPLATIN TREATMENT;

D O I：

10.1007/BF00308789

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

In order to decrease the perioperative complications by preoperative cisplatin chemotherapy, the preoperative single administration of cisplatin (30 mg/m2) was performed weekly from one to six times in 36 consecutive patients with esophageal cancer classified as higher than Stage II. The survival curve of 17 patients in Stage III was significantly better (P < 0.05) than that of patients who had been treated without preoperative cisplatin treatment. In 3 of the 12 patients who had locally invasive cancer, either the main tumors or the metastatic lymph nodes, which had invaded the trachea or the left main bronchus, sufficiently receded, so that a curative esophagectomy became possible; 2 of them have survived over 33 months while 1 died of pneumonia 33 months after surgery. The number of perioperative complications was minimal, and thus, we consider that the postoperative use of cisplatin and fluorouracil is indicated in patients in whom a histological response is noted in the resected specimens.

引用

页码：409 / 415

页数：7

共 19 条

[1]

Parameters linked to 10-year survival in Japan of resected esophageal carcinoma, Chest, 96, pp. 1005-1011, (1989)

[2]

Peracchia A., Debesi P., Castoro C., Et al., Results of surgery after cispaltin and 5-FU combination chemotherapy for locally advanced esophageal squamous cell carcinoma, Diseases of the esophagus, pp. 299-303, (1990)

[3]

Wolfe W.G., Burton G.Y., Steiger H.F., Et al., Early results with combined modality for carcinoma of the esophagus, Ann Surg, 205, pp. 563-571, (1987)

[4]

Stewart I.M., Harkins B.J., Hahn S.S., Daniel T.M., Cisplatin, 5-fluorouracil, mitomycin, and concurrent radiation therapy with and without esophagectomy for esophageal carcinoma, Cancer, 64, pp. 622-628, (1989)

[5]

Kolaric K., Roth A., Zupanc D., Leutic J., Tometic Z., Combined cis-platinum plus radiation antitumor activity in locoregionally advanced squamous cell esophageal cancer, Oncology, 45, pp. 276-280, (1988)

[6]

Kelsen D.P., Fein R., Coonley C., Heelan R., Bains M., Cisplatin, vindesine, and mitoguazone in the treatment of esophageal cancer, Cancer Treat Rep, 70, pp. 255-259, (1986)

[7]

Roth J.A., Pass H.I., Flanagan M., Et al., Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus, J Thorac Cardiovasc Surg, 96, pp. 242-248, (1988)

[8]

Leichman L., Steiger Z., Seydel H.G., Et al., Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: A potentially curative approach, J Clin Oncol, 2, pp. 75-79, (1984)

[9]

Hilgenberg A.D., Carey R.W., Wilkins E.W., Et al., Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus, Ann Thorac Surg, 45, pp. 357-363, (1988)

[10]

Desai P.B., Vyas J.J., Sharma S., Et al., Combined treatment modalities in esophageal cancer, Semin Surg Oncol, 5, pp. 365-369, (1989)

← 1 2 →